Clinical Trial Update: Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies [Phase 2]

View source ↗

Summary

Phase 2 trial of PF-03084014 in combination with gemcitabine and nab-paclitaxel in metastatic pancreatic adenocarcinoma was terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• PF-03084014 (nirogacestat)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Cancer Pancreas | Phase 2 | Status: TERMINATED | Results posted: 2017-06-12